| Schedule of Non-Controlling Interests in Consolidated Entities |
Non-controlling interests in consolidated entities are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended |
|
|
|
|
|
|
|
|
As of December 31, 2022 |
|
December 31, 2022 |
|
As of December 31, 2022 |
|
|
|
|
|
Non-controlling interests |
|
Net loss attributable to |
|
Non-controlling interests |
|
Non-controlling |
|
($ in thousands) |
|
equity share |
|
non-controlling interests |
|
in consolidated entities |
|
ownership |
|
Urica |
|
$ |
(2,657) |
|
$ |
(1,251) |
|
$ |
(3,908) |
|
40.2 |
% |
Aevitas |
|
|
(5,328) |
|
|
(425) |
|
|
(5,753) |
|
45.2 |
% |
Avenue 2 |
|
|
5,409 |
|
|
(2,355) |
|
|
3,054 |
|
89.9 |
% |
Baergic3 |
|
|
113 |
|
|
(113) |
|
|
— |
|
— |
% |
Cellvation |
|
|
(1,689) |
|
|
(102) |
|
|
(1,791) |
|
21.3 |
% |
Checkpoint 1 |
|
|
32,398 |
|
|
(48,406) |
|
|
(16,008) |
|
82.2 |
% |
Coronado SO |
|
|
(291) |
|
|
— |
|
|
(291) |
|
13.0 |
% |
Cyprium |
|
|
(2,644) |
|
|
(1,173) |
|
|
(3,817) |
|
29.0 |
% |
Helocyte |
|
|
(5,778) |
|
|
(122) |
|
|
(5,900) |
|
17.9 |
% |
JMC |
|
|
19,887 |
|
|
(12,458) |
|
|
7,429 |
|
43.7 |
% |
Mustang 2 |
|
|
98,461 |
|
|
(60,821) |
|
|
37,640 |
|
81.3 |
% |
Oncogenuity |
|
|
(1,464) |
|
|
(111) |
|
|
(1,575) |
|
27.4 |
% |
Tamid |
|
|
(775) |
|
|
(1) |
|
|
(776) |
|
22.8 |
% |
Total |
|
$ |
135,642 |
|
$ |
(127,338) |
|
$ |
8,304 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended |
|
|
|
|
|
|
|
|
As of December 31, 2021 |
|
December 31, 2021 |
|
As of December 31, 2021 |
|
|
|
|
|
Non-controlling interests |
|
Net loss attributable to |
|
Non-controlling interests |
|
Non-controlling |
|
($ in thousands) |
|
equity share |
|
non-controlling interests |
|
in consolidated entities |
|
ownership |
|
Urica |
|
$ |
(442) |
|
|
(1,353) |
|
$ |
(1,795) |
|
34.5 |
% |
Aevitas |
|
|
(4,159) |
|
|
(901) |
|
|
(5,060) |
|
45.9 |
% |
Avenue 2 |
|
|
5,739 |
|
|
(2,909) |
|
|
2,830 |
|
82.0 |
% |
Baergic |
|
|
(2,047) |
|
|
(39) |
|
|
(2,086) |
|
39.0 |
% |
Cellvation |
|
|
(1,413) |
|
|
(131) |
|
|
(1,544) |
|
21.7 |
% |
Checkpoint 1 |
|
|
63,464 |
|
|
(39,226) |
|
|
24,238 |
|
81.5 |
% |
Coronado SO |
|
|
(290) |
|
|
— |
|
|
(290) |
|
13.0 |
% |
Cyprium |
|
|
(1,397) |
|
|
(807) |
|
|
(2,204) |
|
29.8 |
% |
Helocyte |
|
|
(5,440) |
|
|
(89) |
|
|
(5,529) |
|
18.3 |
% |
JMC |
|
|
23,150 |
|
|
(5,652) |
|
|
17,498 |
|
41.6 |
% |
Mustang 2 |
|
|
141,527 |
|
|
(48,518) |
|
|
93,009 |
|
82.7 |
% |
Oncogenuity |
|
|
(627) |
|
|
(497) |
|
|
(1,124) |
|
24.9 |
% |
Tamid |
|
|
(739) |
|
|
(1) |
|
|
(740) |
|
22.8 |
% |
Total |
|
$ |
217,326 |
|
$ |
(100,123) |
|
$ |
117,203 |
|
|
|
Note 1: Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.
Note 2: Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Class A Preferred Shares which provide super-majority voting rights.
Note 3: Fortress’ ownership in Baergic was transferred to Avenue as of November 7, 2022 (see Note 17).
|